Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Irritable Colon Clear all
Not listed Not applicable Interventional

Changes in Microbiota and Quality of Life in IBS

NCT05266287
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
a supplement containing 2'-fucosyllactose (2'-FL), Placebo Supplement
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

NCT02590432
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
79
States / cities
Anniston, Alabama • Athens, Alabama • Childersburg, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional

Nursing Management of Irritable Bowel Syndrome:Improving Outcomes

NCT00167635
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
cognitive-behavioral
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2009 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 3 Interventional

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

NCT01100684
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
142
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Irritable Bowel Syndrome and Food Sensitivity

NCT02186743
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Personalized Dietary Advice
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Mindfulness-Based Stress Reduction and the Microbiome

NCT01619384
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Irritable Bowel Syndrome
Interventions
Mindfulness-Based Stress Reduction
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Delivered Dietary Intervention for Children With Irritable Bowel Syndrome

NCT01339117
View directory record Official record
Conditions
Irritable Bowel Syndrome, Abdominal Pain
Interventions
Low fermentable substrate diet, High fermentable substrate diet
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DNK333
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 24, 2026, 5:26 AM EDT
Not listed Not applicable Interventional

Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.

NCT01297556
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Cognitive Behavior Therapy(CBT)
Behavioral
Lead sponsor
Michigan Gastroenterology Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?

NCT00911612
View directory record Official record
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Diet Reintroduction Study in Irritable Bowel Syndrome

NCT03052439
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
FODMAP
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Efficacy of the Mediterranean Diet to the Low- Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Diet in Treating Irritable Bowel Syndrome(IBS)

NCT05807919
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Diet low in all FODMAP groups, Diet - Mediterranean
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

NCT02358694
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Serum-Derived Bovine Immunoglobulin, Placebo
Dietary Supplement · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

NCT00401479
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Placebo, Solabegron (GW427353)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Nursing Management of Irritable Bowel Syndrome (IBS) 2008

NCT00907790
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Usual Care (Control Group), Comprehensive Self-Management (CSM)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT01722318
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
99
States / cities
Birmingham, Alabama • Dothan, Alabama • Glendale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 24, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

NCT07591584
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions
FODMAP-targeting digestive enzyme blend, Placebo
Dietary Supplement · Other
Lead sponsor
Kiwi Health Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01923428
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Boulder, Colorado • Greensboro, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 24, 2026, 5:26 AM EDT
Completed Not applicable Interventional

Effect of Curcumin on Gut Microbiota in IBS

NCT03568513
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Curcumin, Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
10 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 24, 2026, 5:26 AM EDT
Terminated Phase 1 Interventional

The Use of VSL#3 in Irritable Bowel Syndrome in Children

NCT00932841
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Placebo, VSL#3 900 billion bacteria, VSL#3 90 billion bacteria
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 24, 2026, 5:26 AM EDT
Completed No phase listed Observational

Development of a Questionnaire to Measure Hypervigilance for Visceral Pain

NCT01166802
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Oct 24, 2026, 5:26 AM EDT
Terminated Not applicable Interventional Results available

Zemedy Application for Irritable Bowel Syndrome

NCT04723056
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Use of Zemedy Application
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 24, 2026, 5:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Phenotyping IBS: Perceptions and Modulations of Visceral Sensations

NCT02693730
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 24, 2026, 5:26 AM EDT